Biologic Agents in the Treatment of Multicentric Castleman Disease

Turkish Thoracic Journal - Turkey
doi 10.5152/turkthoracj.2018.18066
Full Text
Abstract

Available in full text

Date
Authors
Publisher

AVES Publishing Co.

Related search

FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease

Clinical Cancer Research
Cancer ResearchOncology
2015English

Multicentric Castleman Disease: An Unusual Breast Lump

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease

Immunotherapy
OncologyAllergyImmunology
2016English

Clinicopathologic Characteristics of 342 Patients With Multicentric Castleman Disease in Japan

Modern Rheumatology
MedicineRheumatology
2020English

Multicentric Castleman' S Disease Manifesting in the Lung: Clinical, Radiographic, and Pathologic Findings and Successful Treatment With Corticosteroid and Cyclophosphamide.

Internal Medicine
Internal MedicineMedicine
2003English

Efficacy of Bortezomib in Refractory Form of Multicentric Castleman Disease Associated to Poems Syndrome (MCD-POEMS Variant)

Annals of Hematology
MedicineHematology
2009English

Persistence With Biologic Agents for the Treatment of Rheumatoid Arthritis in Japan

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2016English

Castleman Disease: Delineating the Spectrum

British Journal of Haematology
Hematology
2017English

Complete Remission in a Patient With Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP Chemotherapy

Cancer Research and Treatment
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy